TARO-DESVENLAFAXINE TABLET (EXTENDED-RELEASE)
Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Charakteristika produktu
(SPC)
19-10-2022
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
Dostupné s:
TARO PHARMACEUTICALS INC
ATC kód:
N06AX23
INN (Mezinárodní Name):
DESVENLAFAXINE
Dávkování:
100MG
Léková forma:
TABLET (EXTENDED-RELEASE)
Složení:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100MG
Podání:
ORAL
Jednotky v balení:
15G/50G
Druh předpisu:
Prescription
Přehled produktů:
Active ingredient group (AIG) number: 0152509002; AHFS:
Stav Autorizace:
APPROVED
Datum autorizace:
2022-10-20
Charakteristika produktu
PRODUCT MONOGRAPH
PR TARO-DESVENLAFAXINE
desvenlafaxine extended-release tablets
50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate
monohydrate
)
Antidepressant
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive
OCT 19, 2022
Brampton, Ontario
L6T 1C1
Submission Control No.: 264187
_________________________________________________________________________________________
_Taro-Desvenlafaxine (desvenlafaxine succinate monohydrate) Product
Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFOR
M
ATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
............................................................................................................................11
DRUG INTERACTIONS
.............................................................................................................................21
DOSAGE AND ADMINISTRATION
.........................................................................................................24
OVERDOSAGE
...........................................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................28
STORAGE AND STABILITY
....................................................................................................................31
SPECIAL HANDLING INSTRUCTIONS
.
Přečtěte si celý dokument
